M&A In India May Lose Steam As Potential Sellers Raise Their Price Tags, Investment Bankers Say
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Greed is getting in the way of several prospective mergers and acquisitions in the Indian pharmaceutical industry, two senior investment bankers told PharmAsia News, but reiterated that multinational companies are still keenly scanning companies that fit into their global programs
You may also be interested in...
Japanese Pharma Expects New Deal Model For Next 20 Years - New York Pharma Forum
NEW YORK - When the New York Pharma Forum, a group consisting primarily of Japanese pharmaceutical executives, gathered for its 20th General Assembly, members reflected on their companies' early days in the U.S. and their prospects for the future, when the scope of partnerships between Western pharma and Asia Pacific pharma will begin to change
Japanese Pharma Expects New Deal Model For Next 20 Years - New York Pharma Forum
NEW YORK - When the New York Pharma Forum, a group consisting primarily of Japanese pharmaceutical executives, gathered for its 20th General Assembly, members reflected on their companies' early days in the U.S. and their prospects for the future, when the scope of partnerships between Western pharma and Asia Pacific pharma will begin to change
After The Supply Pact, Will GSK Go For An Equity Deal With Dr. Reddy's?
MUMBAI - Weeks after the Paris-headquartered Sanofi-Aventis acquired Hyderabad-based Shantha Biotechnics to galvanize the French drug maker's preventative vaccines manufacturing, analysts are now predicting a deal between Britain's GlaxoSmithKline and Dr. Reddy's - India's second biggest pharmaceutical company as measured by sales